First, MRE11-deficiency might be a useful marker for tumor prognosis; and second, that MRE11-deficient (dMRE11) tumors might respond better to treatment with topoisomerase 1 poisons than MRE11-proficient (pMRE11) tumors. This evidence concerns the gene MRE11 and neoplasm.